Validating a Proteomic Signature of Severe COVID-19
Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine..
COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19.
DESIGN: Prospective observational cohort study.
SETTING: Two hospitals in the United States.
PATIENTS: One hundred sixty-seven hospitalized adults with COVID-19.
INTERVENTION: None.
MEASUREMENTS AND MAIN RESULTS: We measured 713 plasma proteins in 167 hospitalized patients with COVID-19 using a high-throughput platform. We classified patients as nonsevere versus severe COVID-19, defined as the need for high-flow nasal cannula, mechanical ventilation, extracorporeal membrane oxygenation, or death, at study entry and in 7-day intervals thereafter. We compared proteins measured at baseline between these two groups by logistic regression adjusting for age, sex, symptom duration, and comorbidities. We used lead proteins from dysregulated pathways as inputs for elastic net logistic regression to identify a parsimonious signature of severe disease and validated this signature in an external COVID-19 dataset. We tested whether the association between corticosteroid use and mortality varied by protein signature. One hundred ninety-four proteins were associated with severe COVID-19 at the time of hospital admission. Pathway analysis identified multiple pathways associated with inflammatory response and tissue repair programs. Elastic net logistic regression yielded a 14-protein signature that discriminated 90-day mortality in an external cohort with an area under the receiver-operator characteristic curve of 0.92 (95% CI, 0.88-0.95). Classifying patients based on the predicted risk from the signature identified a heterogeneous response to treatment with corticosteroids (p = 0.006).
CONCLUSIONS: Inpatients with COVID-19 express heterogeneous patterns of plasma proteins. We propose a 14-protein signature of disease severity that may have value in developing precision medicine approaches for COVID-19 pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Critical care explorations - 4(2022), 12 vom: 14. Dez., Seite e0800 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cosgriff, Christopher V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute hypoxic respiratory failure |
|---|
| Anmerkungen: |
Date Revised 16.05.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/CCE.0000000000000800 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34991835X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34991835X | ||
| 003 | DE-627 | ||
| 005 | 20231226043752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CCE.0000000000000800 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM34991835X | ||
| 035 | |a (NLM)36479446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cosgriff, Christopher V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validating a Proteomic Signature of Severe COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. | ||
| 520 | |a COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19 | ||
| 520 | |a DESIGN: Prospective observational cohort study | ||
| 520 | |a SETTING: Two hospitals in the United States | ||
| 520 | |a PATIENTS: One hundred sixty-seven hospitalized adults with COVID-19 | ||
| 520 | |a INTERVENTION: None | ||
| 520 | |a MEASUREMENTS AND MAIN RESULTS: We measured 713 plasma proteins in 167 hospitalized patients with COVID-19 using a high-throughput platform. We classified patients as nonsevere versus severe COVID-19, defined as the need for high-flow nasal cannula, mechanical ventilation, extracorporeal membrane oxygenation, or death, at study entry and in 7-day intervals thereafter. We compared proteins measured at baseline between these two groups by logistic regression adjusting for age, sex, symptom duration, and comorbidities. We used lead proteins from dysregulated pathways as inputs for elastic net logistic regression to identify a parsimonious signature of severe disease and validated this signature in an external COVID-19 dataset. We tested whether the association between corticosteroid use and mortality varied by protein signature. One hundred ninety-four proteins were associated with severe COVID-19 at the time of hospital admission. Pathway analysis identified multiple pathways associated with inflammatory response and tissue repair programs. Elastic net logistic regression yielded a 14-protein signature that discriminated 90-day mortality in an external cohort with an area under the receiver-operator characteristic curve of 0.92 (95% CI, 0.88-0.95). Classifying patients based on the predicted risk from the signature identified a heterogeneous response to treatment with corticosteroids (p = 0.006) | ||
| 520 | |a CONCLUSIONS: Inpatients with COVID-19 express heterogeneous patterns of plasma proteins. We propose a 14-protein signature of disease severity that may have value in developing precision medicine approaches for COVID-19 pneumonia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a acute hypoxic respiratory failure | |
| 650 | 4 | |a adult | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a plasma proteomics | |
| 700 | 1 | |a Miano, Todd A |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew, Divij |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Alexander C |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Heather M |e verfasserin |4 aut | |
| 700 | 1 | |a Kuri-Cervantes, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Pampena, M Betina |e verfasserin |4 aut | |
| 700 | 1 | |a Ittner, Caroline A G |e verfasserin |4 aut | |
| 700 | 1 | |a Weisman, Ariel R |e verfasserin |4 aut | |
| 700 | 1 | |a Agyekum, Roseline S |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Oniyide, Oluwatosin |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Alexandra P |e verfasserin |4 aut | |
| 700 | 1 | |a D'Andrea, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Adamski, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Greenplate, Allison R |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Brian J |e verfasserin |4 aut | |
| 700 | 1 | |a Harhay, Michael O |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Tiffanie K |e verfasserin |4 aut | |
| 700 | 1 | |a Reilly, John P |e verfasserin |4 aut | |
| 700 | 1 | |a Mangalmurti, Nilam S |e verfasserin |4 aut | |
| 700 | 1 | |a Shashaty, Michael G S |e verfasserin |4 aut | |
| 700 | 1 | |a Betts, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Wherry, E John |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Nuala J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care explorations |d 2019 |g 4(2022), 12 vom: 14. Dez., Seite e0800 |w (DE-627)NLM300504969 |x 2639-8028 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:12 |g day:14 |g month:12 |g pages:e0800 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CCE.0000000000000800 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 12 |b 14 |c 12 |h e0800 | ||